Skip to main content

Table 1 Patient demographics and baseline characteristics

From: Tianzhi granule improves cognition and BPSD of vascular dementia: a randomized controlled trial

ItemsTianzhi
(n = 232)
Donepezil
(n = 233)
Placebo
(n = 55)
Gender, male/female154/78149/8435/20
Race, han/other226/6233/054/1
Age, mean (SD)64.72 (9.18)64.31 (9.99)63.95 (9.15)
Education
 Primary school, N (%)82 (35.34)85 (36.48)23 (41.82)
 Middle school and above, N (%)150 (64.66)148 (63.52)32 (58.18)
Smoking history, (yes/no)97/13496/13624/31
Drinking history, (yes/no)80/15169/16318/37
Neuropsychological score, Mean (SD)
 VADAS-cog52.64 (10.59)53.29 (10.17)52.22 (11.36)
 MMSE20.56 (3.36)20.56 (3.24)20.51 (2.97)
 TMT-A112.05 (41.03)113.26 (45.52)124.69 (47.46)
 TMT-B208.42 (87.42)209.42 (88.92)235.83 (71.05)
 ADL15.15 (9.62)14.66 (9.76)14.87 (8.81)
 CDT2.48 (1.21)2.53 (1.20)2.35 (1.27)
 NPI5.31 (5.52)5.35 (4.91)5.40 (5.51)
  1. VADAS-cog vascular dementia assessment scale-cognitive subscale, NPI Neuropsychiatric Inventory, MMSE mini-mental state examination, ADL activity of daily living scale, CDT clock drawing test, TMT-A trail making test part A, TMT-B trail making test part B
\